oral glp-1 meds The challenge of developing alternatives to Ozempic, Wegovy and Mounjaro Clinically backed oral GLP GLP-1 drugs: Lower dose or

Several factors contribute to it: High research and development costs: These medications required years of research, clinical trials, and safety testing, which collectively cost manufacturers billions of dollars before they were approved

These medications are injectable artificial satiety

This editorial highlights the long, costly and low-success pathway of CNS drug development, the absence of new psychiatric active substances receiving positive EMA opinions between 2020 and 2024, and persistent underinvestment despite rising clinical burden

Tirzepatide (GLP-2) Tirzepatide is a dual-action peptide that enhances insulin sensitivity while suppressing appetite